San Mateo, CA, United States of America

Megan Eileen Bolitho


Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2013

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Megan Eileen Bolitho: Innovator in Bacterial Pathogenicity Treatment

Introduction

Megan Eileen Bolitho is a prominent inventor based in San Mateo, CA. She has made significant contributions to the field of microbiology, particularly in understanding bacterial pathogenicity. Her innovative work has led to the development of methods that could potentially revolutionize the treatment of bacterial infections.

Latest Patents

Megan holds a patent titled "Identification of bacterial autoinducer and use in treating bacterial pathogenicity." This patent describes the purification and structural identification of a bacterial autoinducer known as CAI-1. The patent outlines methods for synthesizing the autoinducer and its analogues, as well as their applications in treating bacterial pathogenicity and biofilm formation. Notably, it includes strategies for preventing and treating cholera. The synthetic compound (S)-3-hydroxytridecan-4-one has been shown to function similarly to natural CAI-1 in repressing the production of the virulence factor toxin co-regulated pilus (TCP). The patent emphasizes the potential for manipulating bacterial quorum sensing in clinical settings.

Career Highlights

Megan is affiliated with Princeton University, where she continues her research and innovation in microbiology. Her work has garnered attention for its potential impact on public health and disease prevention. With a focus on bacterial communication and pathogenicity, she is at the forefront of developing new therapeutic strategies.

Collaborations

Megan has collaborated with notable scientists in her field, including Bonnie L. Bassler and Martin F. Semmelhack. These collaborations have enriched her research and expanded the scope of her innovations.

Conclusion

Megan Eileen Bolitho is a trailblazer in the field of bacterial pathogenicity treatment, with her innovative patent paving the way for new therapeutic approaches. Her contributions to microbiology are significant and hold promise for future advancements in healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…